Key Developments: Sagent Pharmaceuticals Inc (SGNT.OQ)
21.26USD
1:02pm EDT
$-0.42 (-1.94%)
$21.68
$21.74
$21.74
$20.88
7,412
37,501
$23.25
$12.66
Latest Key Developments (Source: Significant Developments)
Sagent Pharmaceuticals Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 Net Income Guidance
Sagent Pharmaceuticals Inc announced that for fiscal 2013, it expects net revenue to be in the range of $220 million to $250 million. Based upon the above assumptions and first quarter performance, the Company has expanded its anticipated range for reported net income for fiscal 2013 to between $5 million and $15 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $238 million and net income of $2.4 million for fiscal 2013. Full Article
Sagent Pharmaceuticals Inc Appoints James M. Hussey as President
Sagent Pharmaceuticals Inc announced that its Board of Directors has appointed James M. Hussey as its President, effective March 25, 2013. Full Article
Sagent Pharmaceuticals Inc Issues FY 2013 Guidance In Line With Analysts' Estimates
Sagent Pharmaceuticals Inc announced that for fiscal 2013, it expects net revenue to be in the range of $220 million to $250 million and net income to be in the range of breakeven to $5 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $244 million and net income of $5 million for fiscal 2013. Full Article
Sagent Pharmaceuticals Inc Announces Launch Of Flumazenil Injection USP
Sagent Pharmaceuticals Inc announced that the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV Measures SM packaging and labeling, designed to help reduce medication errors. Full Article
Sagent Pharmaceuticals Inc Announces Launch of Nafcillin for Injection, USP
Sagent Pharmaceuticals Inc announced the launch of Nafcillin for Injection, USP, in two vial presentations and one pharmacy bulk package bottle; all three are latex-free and preservative-free. According to IMS, for the 12 months ending September 2012, the US market for Nafcillin approximated $62 million. As with all products in Sagent's portfolio, Nafcillin features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors. Full Article
Sagent Pharmaceuticals Inc Reaffirms FY 2012 Guidance-Conference Call
Sagent Pharmaceuticals Inc announced that for fiscal 2012, it continues to expects net revenue to be in the range of $180 to $200 million and net loss to be in the range of $20 to $30 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $186 million and net income of $(23.06) million for fiscal 2012. Full Article
Sagent Pharmaceuticals Inc Announces the Launch of Leucovorin Calcium for Injection
Sagent Pharmaceuticals Inc announced the launch of Leucovorin Calcium for Injection, a folic acid derivative, and an adjuvant in antineoplastic agent therapy, in four latex-free and preservative-free vial presentations. According to IMS, for the 12 months ending June 2012, the US market for Leucovorin Calcium for Injection approximated $14 million. As with all products in Sagent's portfolio, Leucovorin features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors. Full Article
Sagent Pharmaceuticals Inc Announces Launch Of Vancomycin Hydrochloride for Injection, USP
Sagent Pharmaceuticals Inc announced that the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 5 gram pharmacy bulk package presentation. According to IMS, for the 12 months ending June 2012, the US market for Vancomycin Hydrochloride for Injection, USP approximated $186 million of which about fifty percent of the sales was pharmacy bulk packages. As with all products in Sagent's portfolio, Vancomycin features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors. Full Article
Sagent Pharmaceuticals Inc Lowers FY 2012 Guidance
Sagent Pharmaceuticals Inc announced that for fiscal 2012, it expects net revenue to be in the range of $180 to $200 million and net loss to be in the range of $20 to $30 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $221 million and net income of $(8.63) million for fiscal 2012. Full Article
Sagent Pharmaceuticals Inc Announces Launch of Oxacillin for Injection, USP
Sagent Pharmaceuticals Inc announced the launch of Oxacillin for Injection, USP, in three latex-free, preservative-free vial presentations. According to IMS data for the 12 months ended May 2012, the U.S. market for Oxacillin approximated $29 million. As with all products in Sagent's portfolio, Oxacillin features the Company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors. Oxacillin for Injection, USP is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Full Article

Earnings vs.
Estimates